ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

ClinicalTrials.gov ID: NCT01642602

Public ClinicalTrials.gov record NCT01642602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Study identification

NCT ID
NCT01642602
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Takeda
Industry
Enrollment
104 participants

Conditions and interventions

Interventions

  • Dexlansoprazole Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2012
Primary completion
Dec 31, 2013
Completion
Dec 31, 2013
Last update posted
Aug 5, 2014

2012 – 2014

United States locations

U.S. sites
35
U.S. states
23
U.S. cities
35
Facility City State ZIP Site status
Not listed Huntsville Alabama
Not listed Mobile Alabama
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Anaheim California
Not listed Los Angeles California
Not listed San Francsco California
Not listed Centennial Colorado
Not listed Thornton Colorado
Not listed Miami Florida
Not listed Atlanta Georgia
Not listed Chicago Illinois
Not listed Park Ridge Illinois
Not listed Indianapolis Indiana
Not listed Louisville Kentucky
Not listed Boston Massachusetts
Not listed Flint Michigan
Not listed Plymouth Minnesota
Not listed Jackson Mississippi
Not listed Kansas City Missouri
Not listed Mays Landing New Jersey
Not listed Brooklyn New York
Not listed Huntsville North Carolina
Not listed Toledo Ohio
Not listed Youngstown Ohio
Not listed Greenville South Carolina
Not listed Kingsport Tennessee
Not listed Fort Worth Texas
Not listed Houston Texas
Not listed Laredo Texas
Not listed San Antonio Texas
Not listed Ogden Utah
Not listed Salt Lake City Utah
Not listed Fairfax Virginia
Not listed Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01642602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 5, 2014 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01642602 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →